Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intas' MD On Acquiring Best-Performing Assets And Brexit

Executive Summary

India's largest privately held pharmaceutical company, Intas, says that it understands Europe well and that the best-performing assets acquired from Teva there are a "perfect fit" for its business. Intas vice chair and managing director Binish Chudgar spoke to Scrip on the buyout and why Brexit isn't a major concern - at least for now.

You may also be interested in...



Aurobindo Aims For Europe Growth With Apotex Acquisitions

The Indian drug maker is handing over €74m to Canada's Apotex, buying the latter's operations in Poland, the Czech Republic, the Netherlands, Spain and Belgium and adding over 200 generics and more than 80 OTC products to its portfolio.

Aurobindo Aims For Europe Growth With Apotex Acquisitions

The Indian drug maker is handing over €74m to Canada's Apotex, buying the latter's operations in Poland, the Czech Republic, the Netherlands, Spain and Belgium and adding over 200 generics and more than 80 OTC products to its portfolio.

Intas Builds Europe Scale With £603m Teva Deal

Intas Pharmaceuticals of India has acquired certain Teva assets in Europe – a transaction that is expected to give the unlisted Indian group significantly expanded scale in the region.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel